» Articles » PMID: 36706896

Association Between Urinary Phthalate Biomarker Concentrations and Adiposity Among Postmenopausal Women

Abstract

Background: Obesity is a leading risk factor for chronic diseases, potentially related to excess abdominal adiposity. Phthalates are environmental chemicals that have been suggested to act as obesogens, driving obesity risk. For the associations between phthalates and adiposity, prior studies have focused primarily on body mass index. We hypothesize that more refined measures of adiposity and fat distribution may provide greater insights into these associations given the role of central adiposity in chronic disease risk.

Objectives: To evaluate associations between urinary phthalate biomarkers and both visceral and subcutaneous adipose tissue (VAT and SAT) among postmenopausal women enrolled in the Women's Health Initiative (WHI).

Methods: We included 1125 WHI participants with available, coincident measurements of urinary phthalate biomarkers (baseline, year 3) and VAT and SAT (baseline, year 3, year 6). VAT and SAT measurements were estimated from DXA scans. Multilevel mixed-effects models estimated the prospective associations between urinary phthalate biomarkers at baseline and VAT and SAT three years later.

Results: In multivariable adjusted models, we observed positive associations between some phthalate biomarkers, including the sum of di-isobutyl phthalate (ΣDiBP) biomarkers, MCNP, and ΣDEHP, with VAT three years later. For example, we observed positive associations between concentrations of ΣDiBP and VAT (Q4 vs Q1 β = 7.15, 95% CI -1.76-16.06; Q3 vs Q1 β = 10.94, 95% CI 3.55-18.33). Associations were generally attenuated but remained significant after additional adjustment for SAT. MBzP was positively associated with SAT. Other phthalate biomarkers investigated (MEP, MCOP, MCPP, ΣDBP) were not significantly associated with VAT or SAT.

Discussion: Based on robust measures of adiposity, this study provides supportive evidence that higher urinary concentrations of select phthalate compounds were associated with higher VAT levels over time in postmenopausal women. Efforts to replicate these findings are needed.

Citing Articles

Phthalate metabolites and sex steroid hormones in relation to obesity in US adults: NHANES 2013-2016.

Zhang J, Gu W, Zhai S, Liu Y, Yang C, Xiao L Front Endocrinol (Lausanne). 2024; 15:1340664.

PMID: 38524635 PMC: 10957739. DOI: 10.3389/fendo.2024.1340664.


The Role of Endocrine Disruptors Bisphenols and Phthalates in Obesity: Current Evidence, Perspectives and Controversies.

Dalamaga M, Kounatidis D, Tsilingiris D, Vallianou N, Karampela I, Psallida S Int J Mol Sci. 2024; 25(1).

PMID: 38203845 PMC: 10779569. DOI: 10.3390/ijms25010675.

References
1.
Song Y, Hauser R, Hu F, Franke A, Liu S, Sun Q . Urinary concentrations of bisphenol A and phthalate metabolites and weight change: a prospective investigation in US women. Int J Obes (Lond). 2014; 38(12):1532-7. PMC: 4481130. DOI: 10.1038/ijo.2014.63. View

2.
Zoeller R, Vandenberg L . Assessing dose-response relationships for endocrine disrupting chemicals (EDCs): a focus on non-monotonicity. Environ Health. 2015; 14:42. PMC: 4440251. DOI: 10.1186/s12940-015-0029-4. View

3.
Langer R, White E, Lewis C, Kotchen J, Hendrix S, Trevisan M . The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol. 2003; 13(9 Suppl):S107-21. DOI: 10.1016/s1047-2797(03)00047-4. View

4.
Feige J, Gelman L, Rossi D, Zoete V, Metivier R, Tudor C . The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. J Biol Chem. 2007; 282(26):19152-66. DOI: 10.1074/jbc.M702724200. View

5.
Bility M, Thompson J, McKee R, David R, Butala J, Vanden Heuvel J . Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters. Toxicol Sci. 2004; 82(1):170-82. DOI: 10.1093/toxsci/kfh253. View